| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Animal Model |
From the Department of Medicine,*
the Human Immunology
and Cancer Program, and the Department of
Radiology,
University of Tennessee Medical
Center/Graduate School of Medicine, Knoxville, Tennessee; the
Department of Pathology,
University of
Tennessee College of Veterinary Medicine, Knoxville, Tennessee; and the
Instrumentation and Controls Division,§
Oak
Ridge National Laboratory, Oak Ridge, Tennessee
AA amyloidosis can be induced in mice experimentally through injection of certain chemical or biological compounds. However, the usefulness of this approach is limited by its dependence on exogenous inflammatory agents that stimulate cytokines to increase the synthesis of precursor serum amyloid A (SAA) protein and the transitory nature of the pathological fibrillar deposits. We now report that transgenic mice carrying the human interleukin 6 gene under the control of the metallothionein-I promoter had markedly increased concentrations of SAA and developed amyloid in the spleen, liver, and kidneys by 3 months of age. At the time of death about 6 months later, organs obtained from these animals had extensive amyloid deposits. This disease process was apparent radiographically using small-animal computer axial tomography and magnetic resonance imaging equipment. The AA nature of the amyloid was evidenced immunohistochemically and was unequivocally established by sequence analysis of protein extracted from the fibrils. The availability of this unique in vivo experimental model of AA amyloidosis provides the means to assess the therapeutic efficacy of agents designed to reduce or prevent the fibrillar deposits found in AA and other types of amyloid-associated disease.
This article has been cited by other articles:
 |
|
 |
|
  A. Solomon, T. Richey, C. L. Murphy, D. T. Weiss, J. S. Wall, G. T. Westermark, and P. Westermark Amyloidogenic potential of foie gras PNAS, June 26, 2007; 104(26): 10998 - 11001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ray, A. Shakya, D. Kumar, M. D. Benson, and B. K. Ray Inflammation-Responsive Transcription Factor SAF-1 Activity Is Linked to the Development of Amyloid A Amyloidosis J. Immunol., August 15, 2006; 177(4): 2601 - 2609. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ludlage, C. L. Murphy, S. M. Davern, A. Solomon, D. T. Weiss, D. Glenn-Smith, S. Dworkin, and K. G. Mansfield Systemic AA Amyloidosis in the Common Marmoset Veterinary Pathology, March 1, 2005; 42(2): 117 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. T. Blumenthal Amyloidosis: A Universal Disease of Aging? J Gerontol A Biol Sci Med Sci, April 1, 2004; 59(4): M361 - M369. [Full Text] [PDF]
|
|
|
|
|
|
G. Senaldi, M. Stolina, J. Guo, R. Faggioni, S. McCabe, S. A. Kaufman, G. Van, W. Xu, F. A. Fletcher, T. Boone, et al. Regulatory Effects of Novel Neurotrophin-1/B Cell-Stimulating Factor-3 (Cardiotrophin-Like Cytokine) on B Cell Function J. Immunol., June 1, 2002; 168(11): 5690 - 5698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Comenzo and M. A. Gertz Autologous stem cell transplantation for primary systemic amyloidosis Blood, May 29, 2002; 99(12): 4276 - 4282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Brayton, M. Justice, and C. A. Montgomery Evaluating Mutant Mice: Anatomic Pathology Veterinary Pathology, January 1, 2001; 38(1): 1 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hrncic, J. Wall, D. A. Wolfenbarger, C. L. Murphy, M. Schell, D. T. Weiss, and A. Solomon Antibody-Mediated Resolution of Light Chain-Associated Amyloid Deposits Am. J. Pathol., October 1, 2000; 157(4): 1239 - 1246. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
